Mobile

A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. 2% MINOXIDIL SOLUTION IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROG...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-018109-29

A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. 2% MINOXIDIL SOLUTION IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECIA)

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the risk/benefit profile of a 5% minoxidil topical foam (MTF) formulation applied OD for the treatment of female pattern hair loss FPHL) in comparison to 2% minoxidil topical solution (MTS) formulation used BID, using objective efficacy measures and safety assessments.

Critère d'inclusion

  • FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECIA)

Liens